SCHEMBL6073686

SCHEMBL6073686

CC(C)(C)NC(=O)Nc1nc2nc(Nc3ccc(N4CCNCC4)cc3)ncc2cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 5/20 0.49
CCND1 P24385 4/20 0.49
CCNA2 P20248 4/20 0.49
CDK2 P24941 4/20 0.49
BRD4 O60885 4/20 0.49
JAK2 O60674 3/20 0.49
SYK P43405 2/20 0.47
WEE1 P30291 2/20 0.46
PTK2 Q05397 1/20 0.46
PLK1 P53350 1/20 0.46
MAPK8 P45983 1/20 0.46
MAPK9 P45984 1/20 0.46
MAPK10 P53779 1/20 0.46
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
FGFR1 P11362 2/20 0.46
FGFR2 P21802 2/20 0.46
FGFR4 P22455 2/20 0.46
FGFR3 P22607 2/20 0.46
STAT6 P42226 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073723 0.90 CDK4 (0.49) CDK4CCND1CCNA2CDK2BRD4
SCHEMBL6074079 0.90 SYK (0.55) BRD4JAK2SYK
SCHEMBL6073559 0.88 CDK4 (0.49) CDK4CCND1CCNA2CDK2BRD4
SCHEMBL6073724 0.86 FGFR1 (0.44) CDK4CCND1CCNA2CDK2JAK2
SCHEMBL6073732 0.86 FGFR1 (0.44) CDK4CCND1CCNA2CDK2JAK2
SCHEMBL6073994 0.85 CDK4 (0.57) CDK4CCND1CCNA2CDK2BRD4
SCHEMBL6073486 0.85 CDK4 (0.50) CDK4CCND1CCNA2CDK2BRD4
SCHEMBL6073818 0.84 CDK4 (0.55) CDK4CCND1CCNA2CDK2BRD4
SCHEMBL6073910 0.82 FGFR1 (0.50) PDGFRBPDGFRAFGFR1FGFR2FGFR4
SCHEMBL6073958 0.81 FGFR1 (0.41) CDK4CCND1CCNA2CDK2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US claimed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US claimed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 CDK4 19/4885CCND1 79/4885CCNA2 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.